Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment by Duncan Howie et al.
REVIEW ARTICLE
published: 28 August 2014
doi: 10.3389/fimmu.2014.00409
Nutrient sensing via mTOR in T cells maintains a
tolerogenic microenvironment
Duncan Howie, HermanWaldmann and Stephen Cobbold*
SirWilliam Dunn School of Pathology, University of Oxford, Oxford, UK
Edited by:
Claudio Mauro, Queen Mary
University of London, UK
Reviewed by:
Fulvio D’Acquisto, Queen Mary
University of London, UK
Claudio Procaccini, Consiglio
Nazionale delle Ricerche, Italy
RuoningWang, The Research Institute
at Nationwide Children’s Hospital,
USA
*Correspondence:
Stephen Cobbold , Sir William Dunn
School of Pathology, University of
Oxford, South Parks Road, Oxford
OX1 3RE, UK
e-mail: stephen.cobbold@
path.ox.ac.uk
We have proposed that tolerance can be maintained through the induction, byTreg cells, of
a tolerogenic microenvironment within tolerated tissues that inhibits effector cell activity
but which supports the generation of furtherTreg cells by “infectious tolerance.”Two impor-
tant components of this tolerogenic microenvironment depend on metabolism and nutrient
sensing. The first is due to the up-regulation of multiple enzymes that consume essential
amino acids, which are sensed in naïve T cells primarily via inhibition of the mechanistic
target of rapamycin (mTOR) pathway, which in turn encourages their further differentiation
into FOXP3+ Treg cells. The second mechanism is the metabolism of extracellular ATP to
adenosine by the ectoenzymes CD39 and CD73. These two enzymes are constitutively
co-expressed onTreg cells, but can also be induced on a wide variety of cell types byTGFβ
and the adenosine generated can be shown to be a potent inhibitor of T cell proliferation.
This review will focus on mechanisms of nutrient sensing in T cells, how these are inte-
grated with TCR and cytokine signals via the mTOR pathway, and what impact this has
on intracellular metabolism and subsequently the control of differentiation into different
effector or regulatory T cell subsets.
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INTRODUCTION
The mechanistic target of rapamycin (mTOR) signaling acts as a
principle integrator of nutrient-sensing pathways that control and
coordinate the metabolism of the cell according to its need to pro-
liferate or functionally differentiate (1, 2). When a naïve or resting
T cell recognizes its cognate antigen, the activation process involves
synthesis of many new proteins, the induction of rapid cell prolif-
eration, cytokine driven differentiation toward a range of effector
functions, and chemokine induced cell movement to any site of
inflammation. All these processes require a rapid increase in the
main source of energy for the cell, which is ATP. While oxidative
phosphorylation (OXPHOS) by the mitochondria is the most effi-
cient means to generate large amounts of ATP, there seems to be
a switch from primarily OXPHOS in resting T cells to an aero-
bic form of glycolysis, known as the “Warburg effect” (3), during
activation and proliferation (4). This may be because glycolysis
can use glucose as the basic source of carbon to generate many of
the fundamental building blocks of the proliferating cell, such as
amino acids, lipids, complex carbohydrates, and ribonucleotides
(5). The mTOR pathway is strongly implicated in this metabolic
switch because its activation up-regulates the surface expression
of the glucose transporter, Glut1, probably as a result of TCR and
CD28 signaling through phosphatidylinositide 3-kinase (PI3K)
and protein kinase B (PKB also known as AKT) (6). AKT sig-
naling via mTOR also leads to higher expression of amino acid
and other nutrient transporters, such as the transferrin receptor
(7). Signaling downstream of mTOR via ribosomal S6 kinase and
4E-BP1 is also required to initiate protein synthesis from mRNA
at the ribosome (8). Rapamycin is a drug (trade name sirolimus)
that inhibits mTOR by forming a complex with FKBP12, which
binds to raptor and disrupts the activity of the mTORC1 complex.
Rapamycin is used clinically as an immunosuppressive agent, par-
ticularly in allogeneic transplantation, and has over recent years
gained interest as a potential alternative to calcineurin inhibitors,
which not only have renal toxicity but are also thought to block
the induction of regulatory T cells (9).
MECHANISMS OF PERIPHERAL TOLERANCE
REGULATORY T CELLS ARE ENRICHED WITHIN TOLERATED TISSUES
It has recently become clear that tolerance is associated with Treg
cells that act within a highly localized microenvironment to main-
tain a state of acquired immune privilege (10, 11). Tolerance to
skin grafts can be induced using a short course of non-depleting
CD4 antibodies in mice expressing a TRC transgenic, monoclonal
population of CD4+ T cells such that every T cell recognizes the
male antigen presented by MHC-II on the graft (12). This toler-
ance is not due to clonal deletion as the graft recipients contain
normal numbers of male specific T cells, including a proportion
that show evidence of recent activation, by expression of CD44
and IL-2. As these mice are on a RAG−/− background, there are
no FOXP3+ Treg cells present in the naïve animal pre-grafting,
but after tolerance induction, peripherally induced, FOXP3+ Treg
cells are found gradually increasing over time (up to 50%) within
the tolerated graft tissue, but only in small numbers (1–2%) in the
lymph nodes or spleen (12). This suggests that the Treg cells are
acting to control the response of effector T cells primarily within
the graft itself.
This can be demonstrated where alloantigen specific toler-
ance has been induced to a skin graft (e.g., by a short period
of coreceptor blockade with non-depleting anti-CD4 and CD8
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monoclonal antibodies), and then that tolerated graft has been
removed and re-transplanted onto a secondary recipient with no
immune system of its own (e.g., a recombinase activating gene 1
knock out mouse). This skin graft is accepted by the secondary
recipient as it has no T cells to cause any rejection. If, however, we
treat the recipient at the time of graft transfer with monoclonal
antibodies that inactivate or deplete FOXP3+ Treg cells (e.g., anti-
CD25, or if the original recipient carries the hCD2.FOXP3 knock
in reporter, anti-hCD2), the transferred skin grafts are rapidly
rejected (11, 13). This shows that the re-transplanted, originally
tolerated skin graft carried over within it perfectly functional effec-
tor T cells, but that it also contained FOXP3+ Treg cells that were
actively blocking the ability to cause rejection. By studying the
changes in gene expression between tolerated and rejecting skin
grafts, and comparing dendritic cells (DCs) when they interact
with Treg cells in the presence or absence of antigen (14–16), it was
found that while co-stimulatory ligands and antigen presentation
by DCs were down-regulated, there was also an up-regulation of a
number of enzymes that either catabolize or utilize essential amino
acids (EAAs) (17). In the context of a restricted microenvironment
within tissues, where there may not be free exchange of amino acids
and other nutrients with plasma in the vasculature, the local deple-
tion of EAAs by these enzymes could be an effective mechanism
to control the immune response via the mTOR nutrient-sensing
pathway (Figure 1). Conversely, edema and breakdown of the vas-
culature may provide an excess of amino acids that would promote
T cell activation and graft rejection. This regulation by amino acid
availability might be particularly effective if regulatory T cells were
more resistant to the effects of amino acid starvation. It has been
shown that the intracellular concentration of leucine, a particu-
larly strong activator of mTOR, is controlled by a TCR induced
expression of the neutral amino acid transporter slc7a5 in Th1
and Th2 effector T cells, where it is required for their activation
and differentiation, but regulatory T cells seem not to depend on
this particular transporter (18).
IDO MEDIATED TRYPTOPHAN CATABOLISM AS A MECHANISM OF
IMMUNE REGULATION
The maternal immune response to paternal alloantigens expressed
on the developing fetus is in many ways similar to that seen in
transplantation. The expression of the enzyme indoleamine 2,3
dioxygenase (IDO) in the placenta during pregnancy was shown
to be important for avoiding that immune response by the find-
ing that a specific inhibitor, 1-methyl tryptophan, could induce
spontaneous abortion of semi-allogeneic, but not syngeneic, con-
ception (19). In vitro experiments showed that IDO seemed to
act primarily through depletion of tryptophan, although there
is some evidence that the kynurenine products of tryptophan
catabolism may also play a role (20). The tryptophan depletion is
sensed, at least in part, by general control non-repressed 2 (GCN2),
which is one of the initiators of the integrated stress response,
activation of which leads to a block in the proliferation of CD8
effector T cells (21). GCN2 is also required for the survival of T
cells, including CD4+ Treg cells, during periods of amino acid
starvation (17), but it was not essential for T cells to sense the
absence of other EAAs and halt their proliferation in vitro (17).
The in vitro induction of forkhead box P3 (FOXP3) as a result of
FIGURE 1 | A model of infectious tolerance that depends on a nutrient
depleted microenvironment maintained byTreg cells within tissues.
This model proposes that immunological tolerance is maintained within
tissues by the localized depletion of nutrients, particularly the essential
amino acids (EAA), which are required for the proliferation and effector
function of conventional T cells (Tconv). Amino acid depletion is primarily as
a result of regulatory T cells (Treg) inducing (1), in dendritic cells (DC) and
macrophages (Mφ), a range of enzymes that catabolize (2) or utilize EAA
(examples are shown). This lack of EAA is sensed via the mTOR pathway
which, in the presence of TGFβ, encourages the expression of FOXP3, and
the induction of further Treg (3). Under conditions of tolerance the intact
vasculature maintains a barrier between the blood and the tissues, but if
there is inflammation or damage to the vasculature, causing edema, then
EAA can leak into the tissues (4) and contribute to a breaking of the tolerant
microenvironment.
stimulating naïve CD4+ T cells in the presence of low doses of
TGFβ was also unaffected by activating the GCN2 pathway with
histidinol (an inhibitor of histidyl-tRNA synthetase) while in con-
trast, inhibition of the mTOR pathway with rapamycin gave a
synergistic increase in FOXP3 expression (17). It has recently been
found that tryptophan levels can be sensed via mTOR and PKCθ
signaling (22).
DEPLETION OF ESSENTIAL AMINO ACIDS MAINTAIN AN IMMUNE
PRIVILEGED MICROENVIRONMENT WITHIN TOLERATED TISSUES
Indoleamine 2,3 dioxygenase may have been the first example of
immune regulation due to amino acid catabolism because tryp-
tophan is thought to be present at the lowest concentration of all
the EAAs, at least in the plasma. Recently, it has been shown that
mast cells that seem to be specifically associated with tolerated
skin grafts, express the enzyme tryptophan hydroxylase (TPH1)
(23), which utilizes tryptophan to synthesize serotonin. TPH1
knockout mice, unlike wild type controls, could not be made tol-
erant of allogeneic heart grafts using costimulation blockade, but
this could be reconstituted with wild type mast cells. Providing
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5-hydroxytryptophan to bypass the defect in serotonin synthesis
in TPH1 knockout mice was not sufficient to allow the induction
of tolerance, suggesting that the mechanism was dependent on
tryptophan depletion rather than serotonin synthesis (24). Simi-
larly, arginase (ARG1) expression has been implicated in regulating
the immune response during pregnancy (25, 26) and has also
been associated with a presumed protective, type 2, population of
macrophages within tissues (27). Arginine is the substrate for the
inducible form of nitric oxide synthase (iNOS), which is normally
associated with classically activated macrophages and a Th1 effec-
tor cell response, but under limiting concentrations of arginine
in vitro, both arginase and iNOS can cause sufficient depletion of
arginine to cause mTOR inhibition and subsequently block T cell
proliferation (17). Another enzyme called IL4-induced 1 (IL4i1)
for its induction in myeloid cells under Th2 conditions, depletes
EAAs with hydrophobic side chains such as phenylalanine (28).
IL4i1 was also found to be induced in DC when co-cultured with
Treg cells (17).
Expression of many of these EAA consuming enzymes could
be induced within skin grafts in vivo (17) and in DCs in vitro (17)
by a cognate interaction with antigen specific Treg cells, either
by specific cytokines such as TGFβ, IL4, or interferon-γ (IFN-γ)
or via cell surface interactions such as CTLA4 (17). In addition,
catabolic enzymes specific for threonine (threonine dehydroge-
nase – TDH) and the branched chain amino acids (branched chain
amino acid aminotransferase – Bcat1) were more closely associ-
ated with the inflammation and wound healing even when skin was
grafted onto recipients with no adaptive immune system (17). This
suggests that tissues such as skin have a built in nutrient-sensing
mechanism for protecting themselves against immune attack that
might be important for maintaining self-tolerance, which might
explain why long-term surviving, fully healed in syngeneic skin
grafts also had higher levels of these particular enzymes, as well as
an increased infiltration by FOXP3+ Treg cells (16).
All these observations led us to propose that tolerance may
be maintained by regulatory T cells that induce a tolerogenic
microenvironment within tissues that is, at least in part, dependent
on the induction of many different enzymes that deplete the local
pool of EAAs. This lack of EAAs is sensed by T cells via the mTOR
pathway, which inhibits the generation and function of effector T
cells, while encouraging the development of further FOXP3+ Treg
cells (Figure 1). This mechanism may explain the phenomenon
known as “infectious tolerance” where it was shown that naïve T
cells that co-existed with regulatory T cells in a tolerant environ-
ment acquired all the properties of the original tolerant T cells
within 3 weeks, such that tolerance was maintained if the origi-
nal cohort of tolerant T cells were subsequently depleted (29). The
question then arises as to how the consequent inhibition of mTOR
regulates the activation and differentiation of different functional
T cell subsets.
mTOR INTEGRATES NUTRIENT SENSING AND ACTIVATION
SIGNALS IN T CELLS
THE mTOR PATHWAY IN T CELLS
The mTOR pathway (Figure 2) acts generally to coordinate many
aspects of cell growth and metabolism, including the response to
hypoxia and the biogenesis and oxidative capacity of mitochondria
FIGURE 2 |The mTOR pathway inT cells. The mechanistic target of
rapamycin (mTOR) is a component of both the TORC1 and TORC2 signaling
complexes. The TORC1 complex acts as the main integrator of many
different signals (input signals shown in blue text) from nutrients such as
glucose, via TORC2, the TCR, costimulation and growth factors, via PI3K
and AKT, and amino acids via the regulator complex. Hypoxia and AMP
levels are also sensed via AMPK and TSC1/2. AKT activation downstream of
TORC2 is important for cell survival, drives the expression of the glucose
receptor (Glut1) and glycolytic metabolism, and is required for the
differentiation into Th2 cells (outputs of signaling shown outlined in red).
TORC1 is important for the initiation of mRNA translation via S6K1
mediated phosphorylation of the ribosomal protein S6, and the
up-regulation of amino acid transporters at the cell surface. TORC1 also
activates lipid oxidation and cell proliferation while it inhibits the expression
of FOXP3 and Treg differentiation in favor of Th1 and Th17 cells. The sites
where three different clinically available drugs (rapamycin, fingolimod, and
metformin) impact on the mTOR pathway are indicated (orange boxes).
(30). mTOR forms two distinct complexes that seem to have dif-
ferent signaling functions (TORC1 and TORC2) (31). TORC1 is
thought to be the main nutrient-sensing complex and is com-
posed of the serine/threonine kinase mTOR itself, the scaffolding
protein raptor, the positive accessory proteins FKB12, deptor, and
mLST8, and a regulatory subunit PRAS40 that is a target of AKT
downstream of PI3K signaling (32). Most signals, which eventu-
ally lead to activation of the TORC1 complex, including glucose,
cytokines, growth factors, and costimulation in T cells, do so via
PI3K signaling, which eventually phosphorylates mTORC1 via
the tuberous sclerosis (TSC) 1/2 complex and the ras homolog
expressed in brain (Rheb). Rheb is localized within the cell in
a Rab7+ lysosomal compartment and the interaction between
TORC1 and Rheb is entirely dependent on the sensing of suffi-
cient amino acids. Although the molecular sensor of amino acids
in mammals remains unclear, downstream signaling requires the
four ras-related GTP binding (or RAG GTPase – RRAG) proteins
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(A–D) together with the ragulator complex (33, 34), so that a
lack of available amino acids acts as a potent inhibitor of TORC1
activity. The immunosuppressive drug rapamycin binds to FKB12
and disrupts the formation and function of the TORC1 complex
(35) and therefore has a similar effect on cells as does amino acid
starvation. Conversely, TORC1 activation drives protein synthesis
via phosphorylation of S6K1, which phosphorylates the riboso-
mal protein S6 and initiates the translation of messenger RNA. At
the same time, 4E-BP1, an inhibitor of protein translation, is also
deactivated by mTOR-mediated phosphorylation.
Much less is known about how the TORC2 complex is regu-
lated: there is some evidence that it senses reactive oxygen species
and is involved in sphingolipid homeostasis at the plasma mem-
brane (36), while it also seems to sense glucose availability via a
cAMP/PKA pathway (37). TORC2 is thought to be negatively regu-
lated by TORC1 activity via Sin1 phosphorylation (38). Rapamycin
therefore indirectly activates TORC2 in the short term, but chronic
long-term inhibition (over hours to days) of TORC1 (39) or by
amino acid starvation (40) seems to eventually reduce the activity
of TORC2. TORC2 controls various spatial aspects of cell growth,
in particular cell polarity and responses to chemotactic signals via
G protein coupled activation of RAS (41).
mTOR SIGNALING INHIBITS FOXP3 EXPRESSION
It has long been known that mTOR inhibition by rapamycin is
potently immunosuppressive, partly because it blocks the ability
of T cells to respond to interleukin 2 (IL-2) signaling via PI3K
and consequently their ability to proliferate in response to antigen
(42). More recently, it is has become clear that mTOR signaling
also controls the differentiation of CD4+ T helper cell subsets (43),
and in particular, the expression of the “master” transcription fac-
tor for regulatory T cells, FOXP3. mTOR activation downstream of
the TCR, CD28 costimulation and cytokine mediated PI3K signal-
ing is generally required for the proliferation and differentiation
of effector T cells but this is inhibitory for FOXP3 expression (44,
45). Signaling downstream of the sphingomyelin phosphate recep-
tor (S1PR), which is required for lymphocyte trafficking and exit
from the lymph nodes, can also activate mTOR (46). Interest-
ingly, this pathway is the target of the immunosuppressive drug
known as Fingolimod/FTY720 (47), which also has the potential
to promote Treg cell development (48). Although the exact mech-
anism by which mTOR inhibition enhances FOXP3 expression
has not been clarified, there is some evidence that implicates a
number of different pathways. These could act via poorly defined
effects on FOXP3 translation via inhibition of S6K1 and reduced
phosphorylation of the ribosomal protein S6. Additionally, mTOR
could act either indirectly via suppressor of cytokine signaling 3
(SOCS3) (49, 50) or directly on signal transducer and activator
of transcription 3 (STAT3) downstream of IL-6 and the satiety
hormone leptin (51). Phospho-STAT3 may then compete for the
IL-2 driven STAT5 enhancement of FOXP3 transcription (52). In
addition, FOXO3a (53, 54) and the TGFβ signaling component
SMAD3, two transcription factors promoting FOXP3 expression,
are negatively regulated by AKT downstream of TORC2 (55). Evi-
dence from mice with T cell targeted deficiencies in either raptor
(TORC1) or rictor (TORC2) suggests that TORC1 tends to pro-
mote Th1 differentiation (43) while TORC2 may bias toward Th2
via AKT and PKCθ (56). Inhibition of both complexes seems to
be required for the optimal induction of FOXP3+ Treg cells while
Th17 cell development seems to be independent of TORC2, but is
inhibited by rapamycin in favor of FOXP3+ Treg cells (57).
WHILE mTOR INHIBITION IS REQUIRED FOR FOXP3 EXPRESSION, mTOR
ACTIVATION IS NEEDED FOR REGULATORY FUNCTION
Mechanistic target of rapamycin inhibition therefore seems to be
associated with tolerance and FOXP3+ Treg cell induction, and
this appeared to be confirmed by T cell specific mTOR knock-
out mice, which develop an excess of FOXP3+ Treg cells over Th1
and Th2 effector cells (43). Recent data, however, from FOXP3-
Cre.Raptorfl/fl mice where TORC1 activity has been specifically
knocked out in FOXP3+ Treg cells, indicates that TORC1 acti-
vation is still required for Treg cells to function, as evidenced by
the development of an autoinflammatory condition very similar
to scurfy or FOXP3 deficient mice (58). CD4–Cre.Raptorfl/fl mice,
lacking TORC1 activity in all T cells, however, did not develop
disease, presumably because this also compromised the effec-
tor T cells. This raises the possibility that the optimal induction
and expansion of FOXP3+ Treg cells takes place in the nutrient
depleted microenvironments associated with tolerance, but the
Treg cells only become fully active and proliferative when there
is inflammation that needs to be controlled, which requires a
re-activation of their mTOR pathway. Interestingly, it had pre-
viously been postulated that the optimal functional induction
of FOXP3+ Treg cells required alternate cycles or oscillations of
mTOR inhibition, first to promote induction, and subsequently
mTOR activation to promote proliferation (59).
MODULATION OF FOXP3 EXPRESSION BY ADENOSINE AND HYPOXIA
Hypoxia induced factor (HIF) 1α, another downstream target of
TORC1, has also been implicated either as a positive (60, 61) or
a negative (62, 63) regulator of FOXP3 expression. HIF1α is a
BHLH-Pas transcription factor that has an essential role in the
response of cells to hypoxia and which is able to bind directly
to FOXP3 protein to target it for proteosomal degradation (62).
The level of HIF1α transcription is controlled by NFκβ (64),
but its activity is mainly controlled post-translation by an oxy-
gen mediated ubiquitination and degradation controlled by the
von Hippel-Lindau tumor suppressor complex with additional
positive regulation via a TORC1 mediated phosphorylation (65).
Activation of naïve T cells under hypoxic conditions has also been
suggested to enhance FOXP3 expression and the differentiation to
Treg cells (60), but it is not clear whether this is a direct effect of
HIF1α on FOXP3 expression, or whether it is an indirect effect of
HIF1α feedback inhibition of mTOR (66). Hypoxia is associated
with raised levels of AMP within the cell, and the enzyme AMP
activated protein kinase (AMPK) causes inhibition of mTOR via
TSC1/2 (67, 68).
AMP and adenosine are particularly relevant to immune reg-
ulation, as TGFβ is able to induce in a range of hematopoietic
cells the co-expression of two ectoenzymes, CD39 and CD73 (69)
that are also constitutively expressed on Treg cells (70). These
two enzymes (Figure 3) act at the cell surface to convert extra-
cellular sources of ATP, which is associated with inflammation
and cell necrosis, into the anti-inflammatory product adenosine.
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FIGURE 3 |The generation of extracellular adenosine as a component
of an anti-inflammatory microenvironment. Extracellular ATP arises as a
result of cell death, either from the host or pathogen, as can itself be
inflammatory. The two ectoenzymes CD39 and CD73 are normally
co-expressed constitutively on Treg cells, but can be induced on the surface
of many different cell types, including conventional T cells, dendritic cells,
and macrophages, in the presence of a source of TGFβ. These enzymes
sequentially convert extracellular ATP to AMP and then adenosine.
Adenosine can then act either by binding to the A2A receptor on T cells and
DC, which signals via cAMP or it can be taken up via adenosine
transporters where it is rapidly converted to intracellular AMP by adenosine
kinase. These two signaling pathways act to inhibit inflammation and T cell
proliferation. AMP activated kinase mediated inhibition of the mTOR
pathway can then occur downstream of either signaling pathway.
Extracellular adenosine can generate the second messenger cAMP
within the target cell via activation of specific G protein cou-
pled receptors on the cell surface [e.g., A2AR on T cells (71, 72)]
or it can be directly taken up by specific adenosine transporters
(73) where, once inside the cell, it is rapidly converted to AMP
by adenosine kinase. AMP is also generated in the cell down-
stream of G protein signaling via cAMP, which is subsequently
broken down to AMP by phosphodiesterases. Although there is
evidence that this pathway is relevant to tumors escaping immune
surveillance (74, 75), it remains, however, to be resolved whether
adenosine is as an important component of the anti-inflammatory
microenvironment within tolerated tissues.
T CELLS DISPLAYMETABOLIC AND FUNCTIONAL PLASTICITY
IN RESPONSE TO DIVERSE ENVIRONMENTAL CUES
T cells not only adapt to their environment by changing metabolic
mode, but in addition their chosen fuel source and metabolites,
to a large extent, affect their fate and function (Figure 4). T
cells use glucose and glutamine as their primary source of energy
but can switch to ketone bodies and fatty acid use under certain
circumstances (76). Glucose is the primary substrate for ATP pro-
duction in T cells (77, 78). During glycolysis, glucose is converted
to two molecules of pyruvate and two molecules of ATP in an
FIGURE 4 | EffectorT cells and regulatoryT cells have different
requirements for anabolic and catabolic metabolism. Effector T cells,
proliferating T cells, and cancer cells favor anabolic metabolism using
aerobic glycolysis to fuel energy and cell mass demands during
proliferation. Activation of mTOR drives this metabolic shift. Precursors for
nucleotide synthesis and lipid synthesis are supplied via the pentose
phosphate pathway and the TCA cycle, respectively. Resting regulatory and
memory T cells do not require glycolysis and TCA intermediates for cell
growth and favor catabolic metabolism fueled by β-oxidation of fatty acids
to fuel oxidative phosphorylation. Inhibition of mTOR and activation of
AMPK favor a shift to catabolic metabolism.
oxygen-independent process. Pyruvate generated from glycolysis
is oxidized in the TCA cycle yielding NADH and FADH2, which
is used to fuel OXPHOS. OXPHOS is oxygen dependent and effi-
ciently yields as much as 36 molecules of ATP per molecule of
glucose. In order to mount an effective immune response T cells
must expand rapidly and can achieve doubling times as low as
2–6 h (79). To fuel this expansion T cells undergo a major meta-
bolic shift from primarily catabolic fatty acid oxidation (FAO)
driven OXPHOS to anabolic glycolysis and glutaminolysis during
activation, then revert back to FAO in the memory phase. Glycoly-
sis is an amphibolic process that although less efficient in net ATP
production, fuels rapid T cell growth by providing NADPH and
ribose from the pentose phosphate pathway for reductive biosyn-
thetic reactions and nucleotide synthesis and fuels lipid synthesis
via citrate from the TCA cycle. During this process, glucose is
incompletely oxidized and is fermented to lactate while gluta-
mine is converted to glutamate, aspartate, and ammonia. This shift
to oxygen-independent glycolysis in the context of normoxia has
been termed aerobic glycolysis and is a feature of cancer cells,where
the process is termed Warburg metabolism, reviewed in Ref. (80).
Multiple environmental nutritional signals are integrated by T
cells via mTOR and AMPK to control their choice of metabo-
lism and function. These signals include glucose and glutamine
concentration, oxygen tension, amino acid concentration, lipids,
salt concentration (NaCl), leptin concentration, and ATP:ADP
ratio. In addition, immune-specific inputs such as T cell recep-
tor triggering and co-stimulatory/inhibitory signals and cytokines
are integrated by T cells to change their metabolic mode.
GLUCOSE IS REQUIRED FOR T CELL ACTIVATION
Glucose is critical for T cell activation. It is the primary carbon
source for macromolecules such as lipids and nucleotides in T cells
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and can fuel the pentose phosphate pathway to generate NADPH
reducing equivalents. During activation the T cell increases its
rate of glucose metabolism and up-regulates cell surface Glut1
receptors to transfer glucose from the extracellular space (81, 82).
Concomitant with the increase in surface Glut1, hexokinase is also
upregulated (83, 84) after T cell activation. Hexokinase phospho-
rylates glucose thus trapping it in the cytoplasm and maintaining
a glucose gradient across the plasma membrane to maintain facil-
itated diffusion of glucose. Indeed, even in the presence of glut-
amine, in the absence of glucose T cell survival and proliferation
is severely impaired (77). Effector T cells (Teff) specifically Th17,
Th1, and Th2 are particularly glycolytic and dependent on glu-
cose and accumulate preferentially in Glut1 transgenic mice at the
expense of Treg cells. Treg cells preferentially use fatty acids as a
fuel, their development is enhanced in the presence of excess fatty
acids (78).
GLUTAMINE AS AN IMPORTANT CARBON SOURCE FOR T CELLS
Glutamine is the most abundant amino acid in serum (85) and
has also been implicated in immune regulation (86). It is essential
for T cell activation as a source of nitrogen and as a key anapleu-
rotic substrate enabling nucleotide synthesis and redox control
in addition to fueling metabolism via the TCA cycle following
conversion to α-ketoglutarate. T cells consume glutamine at an
equivalent rate to glucose (87, 88). Activation of T cells triggers a
rapid 5- to 10-fold increase in SNAT1 and SNAT2 (89) (sodium
dependent neutral amino acid transporter) glutamine transporter
expression and glutamine import via a CD28 and ERK/mitogen-
activated protein kinase (MAPK) dependent mechanism. Naïve
T cells transport glutamine into the cell via ASCT2 (slc1a5) (90)
where the concentration of glutamine becomes sufficient to act as
an efflux substrate to drive the system L neutral amino acid trans-
porter slc7a5 in complex with CD98 (slc3a2) to import neutral
amino acids into the cell. Sustained neutral amino acids and glu-
tamine are essential for TCR/CD28 driven mTORC1 activation,
but not other TCR signaling pathways such as MAPK or IKK (90).
Activated TORC1 subsequently prolongs glutamine anapleurosis
by activating glutamate dehydrogenase via indirectly inhibiting
transcription of its inhibitor, SIRT4 (91). Glutamine can fuel the
TCA cycle for anabolic and catabolic metabolism in the presence
or absence of glucose and in the presence of hypoxia (92). Cells
require acetyl coenzyme A for lipid synthesis. During hypoxia or
active proliferation where aerobic glycolysis is engaged glucose
carbons are converted to lactate and diverted away from the TCA
cycle. Under these conditions cells can use reductive metabolism
of α-ketoglutarate as an alternative anaplerotic route to produce
acetyl co-A for the synthesis of lipids (93).
FATTY ACID METABOLISM
Resting naïve T cells, memory CD8 T cells and resting regulatory T
cells share FAO as a common default metabolic mode (78, 94–96).
This metabolic state enhances ATP production through mitochon-
drial OXPHOS while minimizing anabolic processes required for
increased cell mass during proliferation. Environmental lipid con-
centration has a role in determining the fate of differentiating T
cells. Treg cell homeostasis requires environmental lipids, which
activate the nuclear receptors peroxisome proliferator activated
receptor (PPAR)α and PPARγ that function as fatty acid sen-
sors and regulators of lipid metabolism. These receptors promote
FOXP3 expression by CD4 T cells in response to TGFβ (97).
Clinically, PPARγ agonists downregulate the production of pro-
inflammatory cytokines such as IL-6, TNFα, and leptin (98).
Provision of fatty acids to T cells in vitro promotes differentiation
to Treg cells while inhibiting effector differentiation (78). These
observations may explain the severe acute immunosuppression
associated with calorific starvation observed in humans.
DIETARY NaCL AND INFLAMMATION
Recent evidence suggests that dietary sodium chloride concentra-
tion may play a role in controlling inflammation by inhibiting
induction of peripheral Treg cells and favoring the induction of
Th17 and Th2 cells (99, 100). Elevated levels of NaCl by just 40 mM
have been shown to activate p38 MAPK signaling, resulting in
activation of the osmosensitive form of NFAT5 (also known as
TONEBP) leading to activation of serum glucocorticoid kinase
1 (SGK1), an AGC serine/threonine kinase (99). SGK1 has been
shown to govern salt transport and salt homeostasis in multi-
ple cell types dependent on TORC2 activity (101). Raised levels
of salt were shown to turn on SGK1 expression, enhance IL-23R
expression, and augment TH17 cell differentiation (99, 100). Pow-
ell and colleagues showed that after activation by mTORC2, SGK1
promoted T helper type 2 (TH2) differentiation by negatively reg-
ulating degradation of the transcription factor JunB mediated by
the E3 ligase Nedd4-2 (102). The same group also showed that
SGK1 turns off IFN-γ via TCF-1. Sodium chloride concentrations
vary anatomically, the concentration in plasma is approximately
140 mM, whereas in insterstitium and lymph nodes it is much
higher ranging from 160 to 250 mM (103, 104). Thus, it is possible
that sodium concentration limits pro-inflammatory activation of
T cells in the blood while allowing Th17 differentiation in tissues
and lymph nodes.
LEPTIN AS A PRO-INFLAMMATORY CYTOKINE
Leptin is an IL-6-like cytokine produced by adipocytes (termed an
“adipokine”), which acts directly on the hypothalamus as a satiety
hormone and also has effects on metabolism and T cell func-
tions (105, 106). Adipokines are hormones or cytokines secreted by
adipocytes, which have pleiotropic effects on the nutritional status
and immune system of the organism. These include the cytokines
IL-1, IL-6, IFN-γ, TNFα as well as leptin and adiponectin. Lep-
tin is produced at high levels constitutively by regulatory T cells,
which also express the leptin receptor (ObR) (107). Leptin is
required for activated T cell proliferation and cytokine produc-
tion in part via inducing up-regulation of mRNA and surface
expression of the Glut1 receptor and glucose uptake (108). Leptin
in combination with T cell receptor triggering induces activa-
tion of CD4+CD45RA naïve T cells but inhibits activation of
CD4+CD45RO+ memory T cells in humans (109). It skews these
cells to produce pro-inflammatory cytokines including IFN-γ and
TNFα and leptin itself. Leptin functions to negatively regulate Treg
cell activity and proliferation. Leptin deficient mice (ob/ob) and
leptin receptor deficient mice (db/db) have decreased susceptibil-
ity to autoimmunity and increased numbers of Treg cells (107,
110, 111). Neutralization of leptin in Treg cell cultures enhances
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their IL-2 dependent proliferation while maintaining suppressive
function. Thus, leptin appears to function as a feedback control
mechanism to control Treg cell activity in response to nutrient
availability.
SIGNALING MECHANISMS REGULATING T CELL
METABOLISM
mTOR COORDINATES METABOLISM AND T CELL DIFFERENTIATION
The activation of naïve T cells has been primarily associated with
glucose metabolism, even under aerobic conditions, as this not
only provides a source of ATP for energy and effector cell activ-
ity but also generates the precursors for nucleotide synthesis and
lipogenesis that are required for cell proliferation (5). Under con-
ditions of nutrient restriction and mTOR inhibition, however, it
would be expected that T cells would switch to more efficient
pathways of energy generation, such as OXPHOS and FAO, both
of which require active mitochondria. Indeed, it has been shown
that Treg cells have higher levels of AMPK activity, which as we
have seen leads to mTOR inhibition, and this in turn reduces the
expression of the glucose transporter (Glut1) and enhances lipid
oxidation, effects, which can be reversed in Glut1 over-expressing
transgenic mice (78). Multiple intracellular signaling pathways
control the choice of metabolic activity engaged by T cells.
c-Myc
The proto-oncogene c-Myc is a critical positive regulator of both
gylcolysis and glutaminolysis and as such has a potentially impor-
tant role in T cell plasticity. c-Myc and its binding partner max
binds to over 10,000 sites in mammalian genomes at a consensus
E-box sequence CAGCTG (112, 113). c-Myc has a fundamental
role in controlling metabolism. It increases transcription of all
the glycolysis genes (114) and also the glutamine transporters
ASCT2 and SN2 by binding to their promoters (114–116). c-
Myc increases usage of pentose phosphate pathway, glycolysis, and
glutaminolysis (84) and also augments mitochondrial biogenesis
via up-regulation of PGC1 (117–119) and the transferrin recep-
tor TFRC (120), which is necessary to provide iron for the heme
containing proteins of the electron transport chain. Thus, c-Myc
drives cells toward anabolic metabolism, at the same time it pro-
motes cell division via glutaminolysis providing the anaplerotic
substrate aKG needed for synthesis of polyamines required for
T cell proliferation (115). Myc deletion in T cells using inducible
tamoxifen cre-lox systems leads to inhibition of glycolysis and glu-
taminolysis (84). Glutamine deprivation inhibits T cell activation
induced growth and proliferation (84).
ESTROGEN RECEPTOR RELATED RECEPTOR α
Estrogen receptor related receptor α (ERRα) is an orphan recep-
tor, one of three members of a family α, β, and γ, which bind to a
DNA consensus site termed the ERR response element (TNAAG-
GTCA) in multiple genes (121). Despite its name it is not activated
by estrogen or related hormones, but seems to be constitutively
active, having an active ligand binding region in the absence of
ligand (122). ERRα is important in immune reprograming as it
seems to function to “rewire” cells to use glucose for anabolism
(123). The glucose transporter glut1 and glucose uptake are inhib-
ited in ERRα null T cells, and by chemical inhibition of ERR (123).
ERRα physically interacts with PGC1α and PGC1β (124), which
act as co-activators to activate transcription of a number of genes
important for FAO (MCAD, CPT1B), TCA cycle (IDH3A, AC02),
and OXPHOS (CYCS,ATP5B) in multiple cell types (125). Interac-
tion of ERRα with the transcriptional co-repressor RIP140 results
in down regulation of many of the genes, which PGC1α/β acti-
vates (126–128). Acute inhibition of ERRα in T cells results in
their inability to proliferate or differentiate into Th subsets, an
effect, which is rescued for proliferation and Treg cell differenti-
ation, but not Teffector differentiation, by addition of long chain
fatty acids (123). Thus, ERRα functions in T cells to enable them
to prepare for the metabolic demands of proliferation and differ-
entiation into effector subsets by enhancing glucose uptake and
mitochondrial biogenesis.
PGC1α
Peroxisome proliferator activated receptor γ co-activator 1α
(PGC1α) is a transcriptional co-activator, a protein with ability
to enhance transcription factor binding to genes, which has no
specific DNA binding capability of its own. It has a central role in
metabolism being the co-activator for multiple transcription fac-
tors involved in mitochondrial biogenesis (129) and glucose and
fatty acid metabolism (130) and gluconeogenesis (131).
LIVER X RECEPTOR
Liver X receptors (LXRs) are receptors of the nuclear receptor
family, which bind to endogenous oxysterols. LXRs have two iso-
forms, α and β. Both isoforms are expressed by CD4 T cells.
These receptors heterodimerize with the retinoid X receptor (RXR)
and function to modulate cholesterol homeostasis by controlling
genes involved in cholesterol and lipid metabolism including sterol
regulatory element binding protein (SREBP) (132, 133). LXRs
have potent effects on T cell function including inhibition of
lymphocyte proliferation (132). Ectopic expression of LXR was
also shown to inhibit T cell differentiation into Th17 cells via
induction of srebp-1 a protein capable of inhibition of aryl hydro-
carbon receptor (Ahr) binding to the IL-17 gene (134). Agonists
of LXR have been shown to ameliorate experimental autoim-
mune encephalomyelitis (EAE) (134). SREBP-1 has recently been
shown to be essential for coordinating T cell receptor activa-
tion and lipid anabolism in dividing CD8 T cells (135). In the
absence of SREBP-1, CD8 T cells can enter G1 phase of cell cycle
but fail to continue to mitosis due to a lack of sufficient cellular
cholesterol.
Ca2+ SIGNALING
Calcium levels in the mitochondrial matrix are tightly regulated
by mitochondrial Ca2+ uniporters (MCU), which transport Ca2+
across the inner mitochondrial membranes (136). Mitochondrial
sequestration of Ca2+ ions results in positive feedback leading to
activation of plasma membrane CRAC channels and sustained T
cell activation (137, 138). Ca2+ concentration in the mitochon-
drial matrix also has important effects on the rate of the TCA
cycle as three calcium dependent TCA enzymes: 2-oxyglutarate
dehydrogenase, NAD+-isocitrate dehydrogenase, and pyruvate
dehydrogenase are activated by Ca2+ ions leading to increased
mitochondrial metabolism (139).
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MITOGEN-ACTIVATED PROTEIN KINASE
The MAPK family of serine/threonine/tyrosine kinases plays a
central and pleitropic role in transducing diverse signals from the
environment into nuclear transcription factor activation. They
are involved in the cellular responses of T cells to inflamma-
tory cytokines, mitogens, insulin, heat shock, and osmotic stress
[reviewed in Ref. (140)]. MAPK is required for glucose and glu-
tamine uptake and metabolism in T cells in a CD28 dependent
manner and is required for glutaminase activity (89, 141).
AMP ACTIVATED PROTEIN KINASE
AMP activated protein kinase is important in energy homeosta-
sis within the cell and the sensing of hypoxia due to the increase
in AMP to ATP ratio under these conditions [reviewed in Ref.
(142)]. The binding of AMP or ADP allows the phosphoryla-
tion of AMPK, which activated its serine/threonine kinase activity.
AMPK phosporylates acetyl-Co-A carboxylase (ACC1) to inhibit
its lipogenic activity and ACC2 to promote expression of carnitine
palmitoyltransferase (CPT1A), which is the rate limiting factor for
the uptake and oxidation of lipids in the mitochondria. PGC1α
activity (see above) is also promoted by AMPK activation. AMPK
also inhibits TORC1 signaling by phosphorylating TSC1/2 and
enhances autophagy, glucose uptake, and mitochondrial biogen-
esis. The net effect of AMPK activation is to shut down energy
intensive processes and to activate pathways that replenish ATP
levels within the cell.
METABOLIC FEEDBACK AND “MOONLIGHTING” FUNCTIONS
OF METABOLIC ENZYMES
In addition to carrying out metabolic activities, many enzymes of
the glycolytic, pentose phosphate, TCA, and fatty acid metabolism
pathways have dual function and “moonlight” as RNA binding
proteins, transcriptionally controlling their targets in a metabolite
dependent fashion (Figure 5). This area has been well reviewed
(96, 143, 144) so only a few key examples will be highlighted here.
The most thoroughly investigated example of a metabolic
enzyme having a second function in RNA translational control
is cytosolic aconitase/iron regulatory protein 1 – IRP1 (145, 146).
This enzyme functions to convert citrate to isocitrate in the TCA
cycle. It is dependent on replete levels of cellular iron for enzymatic
function as it contains a cubane 4fe–4S iron sulfur cluster respon-
sible for its catalytic activity. In conditions of low iron this cluster
disassembles and converts to IRP1, which is capable of binding to
iron responsive elements (IREs), conserved hairpin structures in
the 3′ UTR of RNAs responsible for iron homeostasis (147). IRP
binds with very high affinity (Kd 5pM) to transferrin receptor RNA
(148) to protect the RNA from degradation and increase transla-
tion. It simultaneously binds to an IRE in ferritin, an iron storage
protein, causing it to become translationally repressed (149). In
this way, the enzymatic activity of the protein, dependent on iron
senses cellular iron levels and acts as a rheostat for iron by adjusting
the translation of RNA encoding proteins involved in iron home-
ostasis. Uptake of iron is also essential for the heme containing
proteins in the electron transport chain, and would be required
for resting Treg cells preferentially engaging FAO and OXPHOS.
Several enzymes of the glycolysis pathway have been shown
to have RNA binding activity. Glyceraldehyde 3 phosphate
FIGURE 5 | Moonlighting functions of metabolic enzymes and
metabolites. Enzymes and metabolites of the glycolysis, TCA cycle, and
electron transport chain play roles in immune function. Enzymes and
substrates in red have been shown to have additional non-metabolic
functions in eukaryotes [reviewed in Ref. (173–176)]. GAPDH can bind to
the 3′UTR of some cytokine genes, inhibiting their translation. Pyruvate
kinase M2 has been shown to have kinase activity for the pro-inflammatory
transcription factor STAT3. Aconitase functions as a rheostat for cellular iron
in addition to its role in the TCA cycle. α-Ketoglutarate is an essential
cofactor for the enzymes TET2 and jumonji-C histone demethylases. ATP
may act as a precursor for extracellular adenosine production and H2O2 has
been shown to possess a signaling role in multiple cytoplasmic and nuclear
pathways.
dehydrogenase (GAPDH), aldolase, lactate dehydrogenase (LDH),
phosphoglycerate kinase (PGK), and glucose 6 phosphate dehy-
drogenase (G6PDH) have been shown to regulate the translation
of immunologically relevant mRNA targets (150–152). GAPDH,
LDH PGK, and G6PDH all share a dinucleotide binding region
termed the Rossman fold (153). This RNA binding region con-
sists of two βαβ folds each of which binds a mononucleotide. The
Rossman fold RNA binding activity is competed for by the din-
ucleotides NAD+, NADH, and ATP. In the case of GAPDH, the
cofactor NAD+ is required for glycolytic activity and inhibits tar-
get RNA binding (150) In this way, when GAPDH is required for
glycolysis and cofactors are abundant its RNA binding ability is
competed for by cofactors and shut off. GAPDH has been shown
to target many RNAs including mRNA (150), tRNA (154), rRNA
(155), and viral RNAs (156). GAPDH mRNA targets include IL-
2, GM-CSF, IFNα (150), GLUT1 (151), and IFN-γ (95) where
it binds to an AU rich region in the 3′ untranslated region. In
the case of IFN-γ, GAPDH comprises a component of the gamma
interferon-activated inhibitor of translation (GAIT) complex (95).
If activated T cells are deprived of glucose, and instead provided
with galactose, then glycolysis cannot take place, and yet the T cells
still activate and proliferate (because galactose provides alterna-
tive precursors for nucleotide synthesis via the pentose phosphate
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pathway), but now because GAPDH has no substrate, it blocks
the translation of IFN-γ. Under these conditions the T cells also
then express other markers of T cell exhaustion such as programed
death 1 (PD-1) (95). The corollary of this is that inducing glycoly-
sis, for example, by mTOR activation, will tend to promote effector
cell differentiation. There are also suggestions that there may be
other examples where metabolic enzymes, for example, hexoki-
nase (157) and IDO (51) can have a secondary, signaling role, in
DC differentiation.
Pyruvate kinase (PK) catalyzes the final step of glycolyis; phos-
phoenolpyruvate to pyruvate. It exists in two differentially spliced
forms in most cells PKM1 and PKM2 (158). Highly proliferat-
ing cells including embryonic cells tumor cells and activated T
cells preferentially express the less efficient form PKM2, which
may support accumulation of glycolytic intermediates necessary
for production of amino acids and nucleotides during prolifera-
tion (96, 159, 160). PKM2 also “moonlights” as a kinase for STAT3
using PEP instead of ATP as a phosphate donor (161). This finding
suggests that the metabolic status of the T cell, anabolic or cata-
bolic, indirectly controls activity of a transcription factor known
to transduce pro-inflammatory signals downstream of diverse
cytokines including interferons, IL-5, IL-6, and leptin. Effector
T cells in anabolic mode might be predicted to enhance transcrip-
tional programs normally associated with these pro-inflammatory
signals.
Treg CELL EPIGENETICS AND METABOLISM
Constitutive expression of FOXP3 has been shown to be essen-
tial for continued Treg cell maintenance of functional tolerance
in vivo (11, 162–164). However, FOXP3 expression on its own
does not seem to be sufficient to enable full differentiation into
the Treg cell lineage. Mature Treg cells have a characteristic epige-
netic “fingerprint” of demethylated genes associated with Treg cell
function, which includes five genes termed the “Treg.me”; FOXP3,
CTLA4, Ikzf2 (Helios), Ikzf4 (Eos), and Tnfrsf18 (GITR) (165,
166). In addition, several hundred proteins have been found to be
associated with FOXP3 in mass spectroscopy screens (167) sev-
eral of which are important for maintaining FOXP3 transcription.
Several important transcription factors including Runx1, NFAT,
and GATA3, which are necessary for FOXP3’s function also asso-
ciate with FOXP3. Importantly, progression along the Treg cell
lineage seems to occur prior to the induction of FOXP3 as several
characteristic Treg cell gene sets can be observed in T cells from
mice with a targeted disruption of the FOXP3 gene into which
GFP has been inserted under the control of the FOXP3 promoter.
FOXP3 is thought to amplify the pre-existing gene profile (168).
Characteristic epigenetic modifications have been shown to be
associated with the FOXP3 gene in mature Treg cell, which are not
present in naïve T cells. An intronic conserved non-coding ele-
ment (CNS2) was discovered to be demethylated preferentially in
stable Treg cells (169, 170). Histones surrounding this region were
also shown to have characteristic modifications of open chromatin
(H3K4me3 and acetyl H4 high) (169). DNA methylation and
histone modification by methylation, acetylations, and phospho-
rylation via the action of methyl transferases, acetyl transferases,
and kinases, respectively, requires cellular metabolites as enzymatic
substrates (171). For example, the sirtuins (histone deacetylases)
and poly ADP ribose polymerases (PARPs) require the coenzyme
NAD+ to function (172). In addition, the TET2 DNA hydroxylases,
involved in demethylation of DNA and the jumonji-C (JmjC) his-
tone demethylases involved in histone demethylation belong to a
group of enzymes called the α-ketoglutarate dependent enzymes,
which require the TCA cycle metabolite α-ketoglutarate to func-
tion in addition to ascorbate, oxygen, and iron. Both these classes
of enzymes are inhibited by the TCA cycle intermediates fumarate
and succinate. It is conceivable that epigenetic changes in Treg
cells required for stability and reprograming to the Treg cell lin-
eage may be influenced by the metabolic program that the cell
adopts in response to environmental stimuli such as glucose or
fatty acid availability.
ARE REGULATORY T CELLS ADAPTED METABOLICALLY FOR
CURRENT AND FUTURE MICROENVIRONMENTS?
The experimental data of Treg cell metabolism are predominantly
derived from in vitro observations of resting Treg cells. These
cell cultures are usually performed in media with a vast molar
excess of EAAs, 10-fold physiological levels of glucose and gluta-
mine and oxygen concentrations in excess of physiological norms.
However, it is well known that Treg cells proliferate vigorously
in vivo and presumably require glycolytic intermediates to fuel
anabolic demand during multiple rounds of mitosis. The ques-
tion remains, what would be the advantage to non-proliferating
Treg cells of adopting FAO and OXPHOS as a default metabolic
mode? We hypothesize that Treg cells are uniquely adapted to
their current and future in vivo environments. While Treg cells
interact with DCs in a tolerant microenvironment they induce
EAA-catabolizing enzyme expression in the DC, forming a zone of
acute EAA starvation. In this situation their catabolic mode pref-
erentially protects them from the effects of amino acid starvation,
and presumably limiting glucose concentrations in inflamed envi-
ronments. In addition, they receive survival signals in the form
of IL-2 from effector T cells, yet produce little IL-2 themselves,
thus, inhibiting further effector T cell proliferation. It is possible
that shifting metabolism to catabolic mode in this situation frees
up “moonlighting” glycolytic enzymes to suppress translation of
pro-inflammatory cytokines by the Treg cells. Expansion of Treg
cell numbers in the draining lymph nodes of inflammatory sites
would elicit a switch to anabolic metabolism under conditions of
sufficient glucose and glutamine, enabling increase in cell mass
and mitosis. The ability to shift from an anabolic expansion mode
to a catabolic suppression mode may be key to Treg cell function,
and presents an attractive target for therapeutic intervention.
CONCLUDING REMARKS
Nutrient sensing and the coordination of metabolism seem to
be inherently associated with the mechanisms of immune reg-
ulation in vivo. The question that then arises is – can any of
these metabolic processes be specifically targeted for manipu-
lating immune responses in transplantation, the treatment of
autoimmune diseases and cancer immunotherapy? Many of these
pathways are common to many different cells in the body and
relying on the immunosuppressive effects of available drugs such
as the mTOR inhibitors may therefore have a variety of unwanted
side effects. Consequently, we need to look either for potential
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target components of these metabolic pathways that are restricted
primarily to immune cells or for ways to amplify the effects of
metabolic inhibitors such that they can be used at doses well below
that which have effects outside the immune system. One way to
achieve this might be to concentrate on the period of immune
reconstitution after lymphocyte depletion when the metabolic
needs of homeostatic proliferation of a small number of residual
T cells could be biased in favor of regulatory T cells.
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